Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emphasys on the Block after FDA Panel Rejection

This article was originally published in Start Up

Executive Summary

Emphasys Medical, following negative recommendation from an FDA panel, put itself up for sale.

You may also be interested in...



Asthmatx Following the Leaders In Defining Alair Sales Strategy

Asthmatx is adopting the commercial strategy of high profile successes including Kyphon, Acclarent, Novacept, Fox Hollow Technologies to roll out its Alair broncial thermoplasty system, which recently received approval from the FDA.

Dealmaking in 2009: A Look Back and A Glance Ahead

This article was excerpted from "Top Device Stories of 2009: A Year of Economic Revival and Regulatory Risk," IN VIVO, January 2010.

Dealmaking in 2009: A Look Back and A Glance Ahead

This article was excerpted from "Top Device Stories of 2009: A Year of Economic Revival and Regulatory Risk," IN VIVO, January 2010.

Related Content

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091730

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel